Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Pooja Agarwal
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
Claims22
A method of delivering a transgene to the skin of a subject, the method comprising administering to the subject a pharmaceutical composition comprising:
- a) a replication-defective herpes simplex type 1 virus (HSV-1) comprising a recombinant herpes simplex type 1 virus genome, wherein the recombinant genome comprises one or more polynucleotides encoding the transgene;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the recombinant genome comprises an inactivating mutation in the infected cell protein 22 (ICP22) herpes simplex virus gene;
- wherein the pharmaceutical composition is administered topically, transdermally, or intradermally to the subject;
- and
- wherein the replication-defective HSV-1 is suitable for delivering the one or more polynucleotides encoding the transgene to one or more target cells of the epidermis and/or dermis of the subject.
A pharmaceutical composition useful for delivery of a transgene to the skin of a subject, comprising:
- a) a replication-defective herpes simplex type 1 virus (HSV-1) comprising a recombinant herpes simplex type 1 virus genome, wherein the recombinant genome comprises one or more polynucleotides encoding the transgene;
- and
- b) a pharmaceutically acceptable carrier;
- wherein the recombinant genome comprises an inactivating mutation in the infected cell protein 22 (ICP22) herpes simplex virus gene;
- wherein the pharmaceutically acceptable carrier is suitable for topical, transdermal, or intradermal administration;
- and
- wherein the replication-defective HSV-1 is suitable for delivering the one or more polynucleotides encoding the transgene to one or more target cells of the epidermis and/or dermis of the subject.
Dependencies are inferred from the claim text.